Pharmaceutical composition for sustained-release delivery of rasagiline mesylate and its preparation method and application
By developing pharmaceutical compositions containing rasagilane methanesulfonate, soy phospholipids and glyceryl dioleate in Parkinson's disease treatment, the problem of fluctuations in blood concentrations of oral drugs and sudden release control of long-acting slow-release preparations has been solved. , achieved a one-week sustained release of rasagilan methanesulfonate, improving the stability and safety of the treatment.
Patent Information
- Application Number
- CN202411169943.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-26
AI Technical Summary
Most of the existing treatment drugs for Parkinson's disease are oral, and there are problems such as large fluctuations in blood concentrations, high risk of side reactions, and difficulty in stopping the drug. Long-acting delayed and controlled release preparations have challenges in drug sudden release control.
Develop a pharmaceutical composition for sustained release delivery of rasagilan methanesulfonate, including rasagilan methanesulfonate, organic solvents and lipid controlled release components, soy phospholipids and glyceryl dioleate, Through a specific formulation process, the drug is superdissolved and slow release in NMP, forming a drug reservoir with a sustained release time of 1 week.
It has achieved a more controlled and sustained release of rasagilane methanesulfonate, reduced the fluctuations in blood concentration and the risks of side reactions, and provided a more stable drug supply, which is of great clinical significance.
Smart Images

Figure CN118680910B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of in situ gelation, and particularly relates to a pharmaceutical composition for sustained-release delivery of rasagiline mesylate, and a preparation method and application thereof. Background Art
[0002] Parkinson's disease (PD) is a common neurodegenerative disease that is more common in the elderly, with an average age of onset of about 60 years old. Parkinson's disease in young people under 40 years old is rare. The prevalence of PD in people over 65 years old in my country is about 1.7%. Its clinical manifestations mainly include resting tremor, bradykinesia, muscle rigidity and posture and gait disorders. At the same time, patients may have non-motor symptoms such as depression, constipation and sleep disorders. The prominent pathological changes of Parkinson's disease are the degeneration and death of dopamine (DA) neurons in the substantia nigra of the midbrain, a significant decrease in the DA content in the striatum, and the appearance of eosinophilic inclusions in the cytoplasm of the remaining neurons in the substantia nigra, namely Lewy bodies. When clinical symptoms appear, at least 50% of the dopamine neurons in the substantia nigra die, and the DA content in the striatum decreases by more than 80%.
[0003] Rasagiline is a second-generation monoamine oxidase inhibitor that blocks the decomposition of the neurotransmitter dopamine. Compared with selegiline (a first-generation monoamine oxidase inhibitor), its inhibitory effect is 5-10 times stronger, and it also improves patients whose long-term use of dopamine preparations has led to a decline in drug efficacy. In addition, the metabolite of rasagiline is an inactive non-amphetamine substance with few side effects. More importantly, the drug has a certain symptom-relieving effect, and there is much evidence that this type of drug has a certain neuroprotective effect. Since Parkinson's patients need to take medication for a long time, and daily oral medication is not easy for patients, which greatly reduces the compliance of oral medications, the development of long-acting preparations is of great significance to patients.
[0004] Long-acting injectables (LAIs) are complex injectables, generally including microspheres, liposomes, nanosuspensions, micelles, in situ gel implants, etc. They can be injected with conventional syringes and needles, and remain at the injection site for a long time and provide continuous drug delivery. Long-acting injectables reduce the number of dosing times and systemic adverse reactions caused by fluctuations in blood drug concentrations on the basis of achieving long-term stable drug release, significantly improving the quality of life of patients. Since such preparations generally have a significant burst release effect, a large amount of drug released in a short period of time may have an adverse effect on the safety of medication. Controlling burst release is the focus and difficulty of research and optimization of such preparations.
[0005] In situ forming gel implant (ISFGI) is a liquid preparation that is injected into the body after mixing the drug with a matrix material dissolved in an organic solvent. The liquid preparation undergoes a solid or semi-solid phase transition due to external environmental stimulation at the injection site to form a local drug reservoir. The organic solvent is usually water-soluble N-methyl-2-pyrrolidone (NMP) and ethanol.
[0006] Compared with injectable microspheres, in situ gel implants have the advantages of simple preparation process, low cost, and high encapsulation efficiency. However, due to the organic solvent used, there is no physical barrier for drug release before gel formation, and it takes a certain amount of time to solidify after injection into the body. Therefore, in situ gel implants usually have a larger initial burst release than microspheres.
[0007] Currently, most of the anti-Parkinson's drugs on the market are only oral tablets, including rasagiline. Oral anti-Parkinson's drugs have major defects, such as large fluctuations in blood drug concentrations, and the risk of causing side effects is significantly higher than that of sustained-release preparations; secondly, oral drugs cannot be stopped suddenly, especially levodopa and large doses of dopamine receptor agonists, to avoid withdrawal malignant syndrome. Therefore, it is of great significance to develop small molecule anti-Parkinson's drugs such as rasagiline into long-acting sustained-release preparations. Summary of the invention
[0008] In order to solve the above technical problems, the present invention provides a pharmaceutical composition for sustained-release delivery of rasagiline mesylate, wherein the composition is a reservoir precursor, which can form a drug reservoir and slowly release the drug after being injected into the body, and the sustained-release time is 1 week, thereby achieving a more controllable sustained-release. The present invention also provides a preparation method and application thereof.
[0009] The pharmaceutical composition for sustained-release delivery of rasagiline mesylate of the present invention comprises rasagiline mesylate, an organic solvent and a lipid controlled-release component, wherein the upper limit of the mass percentage of pure rasagiline in the composition is 6.0wt.%, and the lipid controlled-release component is soybean lecithin and dioleylglycerol.
[0010] Preferably, the organic solvent is NMP, and the weight percentage of the organic solvent in the composition is 5wt.%-35wt.%, more preferably 15wt.%.
[0011] Preferably, soybean lecithin accounts for 50wt.%-60wt.%, more preferably 50wt.% of the lipid controlled release component.
[0012] Preferably, diolein accounts for 40 wt.%-50 wt.% of the lipid controlled release component.
[0013] The method for preparing the pharmaceutical composition for sustained-release delivery of rasagiline mesylate of the present invention comprises the following steps:
[0014] (1) Weigh rasagiline mesylate;
[0015] (2) adding soybean lecithin and an organic solvent to mix and dissolve to obtain solution 1;
[0016] (3) Add dioleylglycerol to solution 1 and mix well to obtain solution 1.
[0017] Preferably, in step (2), the dissolution is promoted by heating, tumbling and mixing, and the heating temperature is 40-50°C, more preferably 50°C.
[0018] The application of the pharmaceutical composition for sustained-release delivery of rasagiline mesylate of the present invention is to inject the composition as a reservoir precursor into the body to form a drug reservoir and slowly release the drug.
[0019] Preferably, the composition is filled into a syringe for use, and a British 21G or 22G needle can be used for injection.
[0020] The non-aqueous solvent of the present invention is NMP, which has been used in long-acting injections. However, the solubility of rasagiline mesylate in NMP is limited. The solubility of rasagiline free base sample and rasagiline mesylate sample in different organic solvents is shown in Table 1 below.
[0021] Table 1 Solubility of Rasagiline Free Base Sample and Rasagiline Mesylate Sample in Solvents
[0022]
[0023] Studies have shown that the solubility of rasagiline mesylate in NMP is limited when the weight ratio of the preparation is more than 6% (based on pure rasagiline), and it cannot be directly and completely dissolved in NMP at the prescribed dosage. The present invention can achieve super dissolution of rasagiline mesylate in NMP under a specific preparation process, wherein the dissolution order is the key factor to achieve super dissolution of rasagiline mesylate, and soybean lecithin can be used as a solubilizer for rasagiline mesylate, significantly increasing its solubility in NMP.
[0024] The sustained release of sustained-release preparations is controlled by lipids. The lipid controlled-release components are soybean lecithin and dioleylglycerol. Adjusting the weight ratio of the two within a certain range can be used to adjust the rate of drug release.
[0025] As can be seen from Table 1, the expected drug loading cannot be achieved in the liquid crystal formulation of rasagiline mesylate using ethanol as the solvent.
[0026] It is known from animal pharmacokinetic experiments that the drug preparation is a reservoir precursor that can be filled into a single syringe and can be injected through a British 21G or 22G needle. After injection into the body, a drug reservoir can be formed and the drug can be slowly released, with a sustained release time of 1 week. After a single dose, a maximum concentration (Cmax) of no more than 400ng / mL is provided in rat plasma for every 12mg of rasagiline (mesylate); a maximum concentration (Cmax) of more than 1300ng / mL is provided in rat plasma for every 12mg of rasagiline (free base). Comparing the solubility of the two in normal saline, rasagiline mesylate is much greater than the free base, which should be a faster release of rasagiline mesylate, but the result is just the opposite. The results of the pharmacokinetic study in rats confirmed that rasagiline mesylate has a longer sustained release than rasagiline free base, which is unexpected.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] The present invention can enable rasagiline mesylate to form a drug reservoir and slowly release the drug, and the sustained release time is 1 week, thereby achieving more controllable sustained release and having important clinical significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 is a dissolution curve diagram of the composition of Example 2 and Comparative Example 8;
[0030] Figure 2 It is a drug-time curve diagram of two rasagiline-loaded long-acting injection solutions tested in rats in Example 2 and Comparative Example 5. DETAILED DESCRIPTION
[0031] The technical solution of the present invention will be clearly and completely described below in conjunction with the accompanying drawings and embodiments.
[0032] Unless otherwise specified, all raw materials used in the examples are commercially available.
[0033] Some raw material information is as follows:
[0034] Rasagiline free base is produced by Hubei Hongxin Ruiyu Fine Chemical Co., Ltd.
[0035] Rasagiline mesylate, Zhejiang Jiuzhou Pharmaceutical Co., Ltd., batch number 259600211101;
[0036] NMP, Shanghai Aladdin Biochemical Technology Co., Ltd., analytical grade;
[0037] Soybean lecithin, Shanghai Taiwei Pharmaceutical Co., Ltd.;
[0038] Glyceryl dioleate, Croda Chemicals Co., Ltd.;
[0039] Example 1
[0040] Weigh 0.47g of rasagiline mesylate into a 5mL vial, add 2.015g of soybean lecithin and 0.5g of NMP, place on a tumbling mixer at 40°C and tumble mix for 12h, the whole thing will be a viscous orange-yellow oily liquid; finally, add 2.015g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0041] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0042] Example 2
[0043] Weigh 0.47g of rasagiline mesylate into a 5mL vial, add 1.89g of soybean lecithin and 0.75g of NMP, place on a tumble mixer at 50°C and tumble mix for 8h, the whole thing will be a viscous orange-yellow oily liquid; finally, add 1.89g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0044] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0045] Example 3
[0046] Weigh 0.47g of rasagiline mesylate into a 5mL vial, add 2.418g of soybean lecithin and 0.5g of NMP, place on a tumble mixer at 40°C and tumble mix for 6 hours, the whole thing will be a viscous orange-yellow oily liquid; finally, add 1.612g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0047] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0048] Example 4
[0049] Weigh 0.47g of rasagiline mesylate into a 5mL vial, add 2.568g of soybean lecithin and 0.25g of NMP, place on a tumble mixer at 40°C and tumble mix for 6 hours, the whole thing will be a viscous orange-yellow oily liquid; finally, add 1.712g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0050] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0051] Example 5
[0052] Weigh 0.47g of rasagiline mesylate into a 5mL vial, add 2.268g of soybean lecithin and 0.75g of NMP, place on a tumble mixer at 50°C and tumble mix for 6 hours, the whole thing will be a viscous orange-yellow oily liquid; finally, add 1.512g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0053] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0054] Example 6
[0055] Weigh 0.3135 g of rasagiline mesylate into a 5 mL vial, add 2.218 g of soybean lecithin and 0.25 g of NMP, place on a tumble mixer at 50°C and tumble mix for 5 hours, the whole thing will be a viscous orange-yellow oily liquid; finally, add 2.218 g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0056] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0057] Example 7
[0058] Weigh 0.157g of rasagiline mesylate into a 5mL vial, add 2.2965g of soybean lecithin and 0.25g of NMP, place on a tumble mixer at 50°C and tumble mix for 3h, the whole thing will be a viscous orange-yellow oily liquid; finally, add 2.2965g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0059] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0060] Example 8
[0061] Weigh 0.47g of rasagiline mesylate into a 5mL vial, add 1.39g of soybean lecithin and 1.75g of NMP, place on a tumble mixer at 50°C and tumble and mix for 2h, the whole thing will be a viscous orange-yellow oily liquid; finally, add 1.39g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0062] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0063] Comparative Example 1
[0064] Weigh 0.47g of rasagiline mesylate in a 5mL vial, add 2.165g of soybean lecithin and 0.2g of NMP, place on a tumbling mixer at 40°C and tumble mix for 12h, the whole is a viscous orange-yellow oily liquid, in which some rasagiline mesylate crystals are not dissolved and suspended; finally, add 2.165g of dioleyl glycerol and mix evenly. Place at room temperature for one week to observe the changes in the preparation.
[0065] The obtained composition was not completely dissolved, and had mesylate crystals suspended therein, and relatively large pieces of soybean lecithin were not completely dissolved. After being left for one week, it was still not completely dissolved.
[0066] Comparative Example 2
[0067] Weigh 0.47g of rasagiline mesylate in a 5mL vial, add 1.209g of soybean lecithin and 0.5g of NMP, place on a tumbling mixer at 40°C and tumble mix for 12h, the whole is a viscous orange-yellow oily liquid, in which a large number of rasagiline mesylate crystals are not dissolved and suspended; finally, add 2.821g of dioleyl glycerol and mix evenly. Place at room temperature for one week to observe the changes in the preparation.
[0068] The obtained composition was not completely dissolved, and had mesylate crystals suspended therein. After being left for one week, it was still not completely dissolved.
[0069] Comparative Example 3
[0070] Weigh 0.47g of rasagiline mesylate in a 5mL vial, add 1.284g of soybean lecithin and 0.25g of NMP, place on a tumbling mixer at 50°C and tumble mix for 8h, the whole is a viscous orange-yellow oily liquid, in which some rasagiline mesylate crystals are not dissolved and suspended; finally, add 2.996g of dioleyl glycerol and mix evenly. Place at room temperature for one week to observe the changes in the preparation.
[0071] The obtained composition was not completely dissolved, and had mesylate crystals suspended therein. After being left for one week, it was still not completely dissolved.
[0072] Comparative Example 4
[0073] Weigh 0.47g of rasagiline mesylate in a 5mL vial, add 1.134g of soybean lecithin and 0.75g of NMP, place on a tumbling mixer at 50°C and tumble mix for 6h, the whole is a viscous orange-yellow oily liquid, some rasagiline mesylate crystals are not dissolved and suspended in it; finally, add 2.646g of dioleyl glycerol and mix evenly. Place at room temperature for one week to observe the changes in the preparation.
[0074] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0075] Comparative Example 5
[0076] Weigh 0.305g of rasagiline free base into a 5mL vial, add 1.9725g of soybean lecithin and 0.75g of NMP, place on a tumble mixer at 50°C and tumble mix for 8h, the whole thing will be a viscous orange-yellow oily liquid; finally, add 1.9725g of dioleyl glycerol and mix evenly. Place at room temperature for one week and observe the changes in the preparation.
[0077] A clear, transparent orange-yellow oily liquid was obtained, which did not change in color after being left at room temperature for a week.
[0078] Comparative Example 6
[0079] Weigh 0.47g of rasagiline mesylate in a 5mL vial, add 1.89g of soybean lecithin and 0.75g of anhydrous ethanol, place on a tumble mixer at 50°C and tumble mix for 12h. The whole is an orange-yellow oily liquid with good fluidity; some rasagiline mesylate crystals are undissolved. Finally, add 1.89g of dioleylglycerol and mix evenly. Place at room temperature for one week to observe the changes in the preparation.
[0080] The obtained composition was not completely dissolved, and had mesylate crystals suspended therein. After being left for one week, it was still not completely dissolved.
[0081] Comparative Example 7
[0082] Weigh 0.47g of rasagiline mesylate into a 5mL vial, add 2.646g of soybean lecithin and 0.75g of NMP, and place on a tumbling mixer at 50°C for continuous tumbling and mixing for 24 hours. The overall solution is an orange-yellow oily liquid with poor fluidity; large pieces of soybean lecithin are not dissolved. Finally, add 1.134g of dioleyl glycerol and mix evenly. Place at room temperature for one week to observe the changes in the preparation.
[0083] The obtained composition was not completely dissolved, and large pieces of soybean lecithin were not dissolved. After being left for one week, the amount of undissolved soybean lecithin was slightly reduced, but still not completely dissolved.
[0084] Comparative Example 8
[0085] Weigh 0.47 g of rasagiline mesylate into a 5 mL vial, add 2.78 g of soybean lecithin and 1.75 g of NMP, and place on a tumbling mixer at 50°C for continuous tumbling and mixing for 24 hours. The whole mixture is an orange-yellow oily liquid with poor fluidity. Place at room temperature for one week to observe the changes in the preparation.
[0086] Although the obtained composition was in a fully dissolved state, its fluidity was extremely poor and its orange-yellow color was darker. After being left for one week, there was no change in fluidity and color.
[0087] Table 2 Dissolution performance test table of Examples 1-8 and Comparative Examples 1-8
[0088]
[0089] As shown in Table 2, comparing Examples 1 and 3 with Comparative Example 2, and Examples 2 and 5 with Comparative Example 4, when the amount of NMP is the same, when the mass ratio of soybean lecithin / diolein is 3 / 7, rasagiline mesylate cannot be completely dissolved, indicating that soybean lecithin is a key component that promotes the dissolution of rasagiline mesylate, and the greater the amount, the better the dissolution-promoting effect. Comparing Examples 2 and 5 with Comparative Example 7, when the amount of NMP is 15%, when the amount ratio of soybean lecithin / diolein is 7 / 3, soybean lecithin cannot be completely dissolved, indicating that the amount of soybean lecithin should not be too large.
[0090] Comparing Examples 1 and 2 with Comparative Example 1, it is shown that the amount of organic solvent is also one of the key factors affecting the dissolution of rasagiline mesylate. When the mass ratio of soybean lecithin / dioleylglycerol is 5 / 5, the amount of NMP is less than 10wt.% and cannot be completely dissolved; Comparing Example 2 with Comparative Example 6, it is shown that when anhydrous ethanol is used as a solvent in the composition of the present invention, the dissolution of rasagiline mesylate is significantly inferior to that of NMP.
[0091] Comparative Example 2 and Comparative Example 8, combined with the in vitro dissolution curve Figure 1 , indicating that in the absence of diolein, even if excessive NMP is added to dissolve soybean lecithin to form a liquid with excessive viscosity, the sustained-release ability is far less than that in the presence of diolein. Diolein is one of the necessary sustained-release materials in the composition.
[0092] Performance Testing
[0093] 1. Release speed test
[0094] The compositions obtained in Example 2 and Comparative Example 8 and rasagiline mesylate were subjected to three parallel tests for in vitro release detection. The dissolution curves are shown in FIG. Figure 1 It can be seen that the drug release time of Example 2 is significantly slower than that of Comparative Example 8 and rasagiline mesylate. Example 2 is completely released in about 24 hours, Comparative Example 8 is basically completely released in about 1 hour, and rasagiline mesylate is completely dissolved before 0.5 hours. The compositions obtained in Example 2 and Comparative Example 8 and rasagiline mesylate are all released close to 100% in about 24 hours.
[0095] 2. Detection of blood drug concentration after subcutaneous injection of rasagiline long-acting injection in SD rats
[0096] The compositions obtained in Example 2 and Comparative Example 5 were taken for in vivo release testing.
[0097] Experimental animal species: SD rats, 6 rats in each group, all were given 0.2 mL of the drug, the dosage was 60 mg / kg, and the injection needle was 22G.
[0098] Blood was collected from the tail vein at 0.25h, 1h, 2h, 4h, 8h, 24h, 2d, 4d, 6d, and 7d after administration. About 0.5mL of blood was collected for each sample and anticoagulated with sodium heparin. The blood samples were centrifuged within 1h after collection to separate the plasma (centrifugation conditions: 8000rpm, 6min, 2-8ºC). The plasma samples were stored in a -80ºC refrigerator before analysis. After 7d, all plasma samples were taken out, thawed, and diluted. The blood drug concentration of each sample was tested, the drug-time curve was fitted, and the pharmacokinetic parameters were calculated. The obtained drug-time curve is shown in Figure 2 .
[0099] The preparation with rasagiline free base as the API reached the highest blood drug concentration in 4 hours, which was much higher than rasagiline mesylate, exceeding 1300ng / mL, which was equivalent to a maximum concentration (Cmax) of about 1300ng / mL for every 60mg / kg of rasagiline. The preparation with rasagiline mesylate as the API reached a peak of about 370ng / mL about 8 hours after administration. The maximum concentration (Cmax) of rasagiline per 60mg / kg did not exceed 400ng / mL, and then entered a stable release period of up to 1 week.
[0100] Comparative Example 5 shows the dissolution state of the preparation after using rasagiline free base. Under normal circumstances, the solubility of rasagiline free base in organic solvents is better than that of mesylate, and its water solubility is even lower. According to common sense, the free base should have better release behavior and stronger sustained-release effect, but the above-mentioned animal pharmacokinetics test results are exactly the opposite.
Claims
1. A pharmaceutical composition for sustained-release delivery of rasagiline mesylate, characterized in that: The invention comprises rasagiline mesylate, an organic solvent and a lipid controlled-release component, wherein the upper limit of the mass percentage of pure rasagiline in the composition is 6.0wt.%, the organic solvent is NMP, and the weight percentage of the organic solvent in the composition is 5wt.%-35wt.%; the lipid controlled-release component comprises soybean lecithin and dioleyl glycerol, and the soybean lecithin accounts for 50wt.%-60wt.% of the lipid controlled-release component.
2. The pharmaceutical composition for sustained-release delivery of rasagiline mesylate according to claim 1, characterized in that: Diolein accounts for 40 wt.%-50 wt.% of the lipid controlled release component.
3. A method for preparing a pharmaceutical composition for sustained-release delivery of rasagiline mesylate according to any one of claims 1 to 2, characterized in that: The steps include: (1) Weigh rasagiline mesylate; (2) adding soybean lecithin and an organic solvent to mix and dissolve to obtain solution 1; (3) Add dioleylglycerol to solution 1 and mix well to obtain solution 1.
4. The method for preparing the pharmaceutical composition for sustained-release delivery of rasagiline mesylate according to claim 3, characterized in that: In step (2), the dissolution is promoted by heating and tumbling mixing, and the heating temperature is 40-50°C.
5. Use of the pharmaceutical composition for sustained-release delivery of rasagiline mesylate according to any one of claims 1 to 2 in preparing a reservoir precursor for injection into a body to form a drug reservoir and release the drug.
6. The use according to claim 5, characterized in that: The composition is filled into a syringe for use.
